ATE555205T1 - Rekombinantes alpha-fetoprotein, verfahren und mittel zur herstellung davon, zusammensetzungen auf basis davon und verwendung davon - Google Patents

Rekombinantes alpha-fetoprotein, verfahren und mittel zur herstellung davon, zusammensetzungen auf basis davon und verwendung davon

Info

Publication number
ATE555205T1
ATE555205T1 AT05764041T AT05764041T ATE555205T1 AT E555205 T1 ATE555205 T1 AT E555205T1 AT 05764041 T AT05764041 T AT 05764041T AT 05764041 T AT05764041 T AT 05764041T AT E555205 T1 ATE555205 T1 AT E555205T1
Authority
AT
Austria
Prior art keywords
afp
fetoprotein
producing
compositions based
activity
Prior art date
Application number
AT05764041T
Other languages
English (en)
Inventor
Sergei Vladimirovich Benevolensky
Alexei Nikolaevich Marchenko
Dmitry Georgievich Kozlov
Sergei Sergeevich Zatsepin
Lyudmila Nikolaevna Shingarova
Igor V Dudich
Lidiya N Semenkova
Dmitry I Dudich
Eduard Borisovich Tatulov
Elena I Dudich
Original Assignee
Eduard Borisovich Tatulov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eduard Borisovich Tatulov filed Critical Eduard Borisovich Tatulov
Application granted granted Critical
Publication of ATE555205T1 publication Critical patent/ATE555205T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05764041T 2004-07-14 2005-07-07 Rekombinantes alpha-fetoprotein, verfahren und mittel zur herstellung davon, zusammensetzungen auf basis davon und verwendung davon ATE555205T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA200400907A EA011606B1 (ru) 2004-07-14 2004-07-14 Способы получения и применения рекомбинантного альфа-фетопротеина
PCT/RU2005/000369 WO2006009492A1 (en) 2004-07-14 2005-07-07 Recombinant alpha-fetoprotein, method and means for preparation thereof, compositions on the base thereof and use thereof

Publications (1)

Publication Number Publication Date
ATE555205T1 true ATE555205T1 (de) 2012-05-15

Family

ID=35785507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05764041T ATE555205T1 (de) 2004-07-14 2005-07-07 Rekombinantes alpha-fetoprotein, verfahren und mittel zur herstellung davon, zusammensetzungen auf basis davon und verwendung davon

Country Status (10)

Country Link
US (1) US7910327B2 (de)
EP (1) EP1807518B1 (de)
JP (1) JP2008506384A (de)
CN (1) CN1993469B (de)
AT (1) ATE555205T1 (de)
DK (1) DK1807518T3 (de)
EA (1) EA011606B1 (de)
ES (1) ES2384863T3 (de)
PT (1) PT1807518E (de)
WO (1) WO2006009492A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
RU2344173C2 (ru) * 2006-10-27 2009-01-20 Институт биохимии им. А.Н. Баха Российской Академии Наук Кассета и рекомбинантная плазмида для зкспрессии и секреции механозависимого фактора роста человека (mgf), штамм saccharomyces cerevisiae - продуцент mgf и способ получения mgf
CA2670341C (en) * 2006-11-28 2015-05-26 University Of Central Florida Research Foundation, Inc. Vigor enhancement via administration of pyrimidine derivatives
EP2326330B1 (de) 2008-09-16 2015-01-07 University Of Central Florida Research Foundation, Inc. Zusammensetzungen zur behandlung oder verzögerung des beginns von haarverlust
KR101259564B1 (ko) * 2009-02-11 2013-04-30 건국대학교 산학협력단 항산화 활성을 가지는 피부 보호용 조성물
CN102993292A (zh) * 2012-12-14 2013-03-27 上海柯莱逊生物技术有限公司 一种afp重组蛋白和体外重组表达的方法
FI20130341A7 (fi) 2013-11-19 2015-05-20 Oy Safemed Ltd Huonosti vesiliukoisten lääkeaineiden kuljetus metalli-ioneilla tasapainotetun alfafetoproteiinin mukana
RU2617943C2 (ru) * 2015-07-17 2017-04-28 Общество с ограниченной ответственностью "Научно-производственное предприятие "Ферментные технологии" (ООО "НПП "Ферментные технологии") Рекомбинантный фрагмент ДНК, кодирующий альфа-фетопротеин (АФП) человека, содержащий "медленные" кодоны, кодирующие лейцин, экспрессионная плазмида, содержащая указанный фрагмент, клетка Saccharomyces cerevisiae, трансформированная указанной плазмидой, и способ получения рекомбинантного АФП человека

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2559592A (en) * 1947-02-21 1951-07-10 Leslie M Button Vapor or fog nozzle
GB718847A (en) * 1952-09-25 1954-11-24 Allman Patents Ltd Improvements in spraying apparatus
GB798645A (en) * 1955-08-05 1958-07-23 Dorman Sprayer Company Ltd Improvements in or relating to spraying nozzles
GB1007304A (en) * 1963-09-16 1965-10-13 Ici Australia Ltd Nozzle
DE2554723C3 (de) * 1975-12-05 1978-11-23 Hans Grohe Gmbh & Co Kg, 7622 Schiltach Schwallbrause
DE2654228C3 (de) * 1976-11-30 1979-05-23 Robert Bosch Gmbh, 7000 Stuttgart Waschanlage für Abdeckscheiben von Kraftfahrzeugleuchten
GB2121318B (en) * 1982-06-01 1985-10-02 Smiths Industries Plc Improvements relating to spray nozzles
US5139936A (en) * 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
FR2624149B1 (fr) * 1987-12-04 1991-04-26 Planchon Alain Guide-jet plat divergent pour installation sanitaire
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
US6331611B1 (en) * 1991-09-27 2001-12-18 Mcgill University Expression and purification of cloned human alpha-fetoprotein
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
US5965528A (en) * 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) * 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
ATE195347T1 (de) * 1992-10-02 2000-08-15 Res Corp Technologies Inc Methoden der erhöhung der sekretion von überexpremierten proteinen
US7101837B1 (en) * 1995-01-24 2006-09-05 Martinex R & D Inc. Recombinant human alpha-fetoprotein as a cell proliferative agent
US6534479B1 (en) * 1995-01-24 2003-03-18 Martinex R & D Inc. Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers
RU2142784C1 (ru) 1997-04-03 1999-12-20 Закрытое акционерное общество Научно-производственный центр "Сибирская природная косметика" Косметическое средство для ухода за кожей "гармония"
RU2142785C1 (ru) * 1997-04-03 1999-12-20 Закрытое акционерное общество Научно-производственный центр "Сибирская природная косметика" Косметическое средство для ухода за кожей "гармония-n" или "гармония-r"
AU2149899A (en) * 1998-01-23 1999-08-09 Novo Nordisk A/S Process for making desired polypeptides in yeast
CA2365843A1 (en) * 1999-03-09 2000-09-14 Atlantic Biopharmaceuticals, Inc. Expression of human alpha-fetoprotein in mammalian cells
JP4447726B2 (ja) * 2000-03-27 2010-04-07 株式会社共立合金製作所 流体噴射ノズル

Also Published As

Publication number Publication date
EP1807518B1 (de) 2012-04-25
US20090233849A1 (en) 2009-09-17
CN1993469A (zh) 2007-07-04
WO2006009492A8 (en) 2006-04-27
EA011606B1 (ru) 2009-04-28
EP1807518A1 (de) 2007-07-18
US7910327B2 (en) 2011-03-22
EA200400907A1 (ru) 2006-02-24
CN1993469B (zh) 2011-07-20
JP2008506384A (ja) 2008-03-06
WO2006009492A1 (en) 2006-01-26
ES2384863T3 (es) 2012-07-13
PT1807518E (pt) 2012-07-16
DK1807518T3 (da) 2012-07-30
EP1807518A4 (de) 2008-04-16

Similar Documents

Publication Publication Date Title
EP4249036A3 (de) Verfahren und produkte zur nukleinsäureproduktion und freisetzung
EP4406585A3 (de) Nukleinsäureprodukte und verfahren zur verabreichung davon
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
WO2007084342A3 (en) Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
EP2857518A3 (de) Zusammensetzungen und Verfahren mit PGL zur gesteigerten Produktion von Isopren
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
PH12012502272A1 (en) Biological materials related to her3
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
EP2641911A3 (de) Zusammensetzungen und Verfahren zur Neuprogrammierung von Zellen ohne genetische Modifikation
ATE555205T1 (de) Rekombinantes alpha-fetoprotein, verfahren und mittel zur herstellung davon, zusammensetzungen auf basis davon und verwendung davon
MX341317B (es) Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.
DE60332993D1 (de) Das biomolekültransduktionsmotiv mph-1-btm und dessen verwendung
Li et al. Novel small-molecule treatment and emerging biological therapy for psoriasis
WO2007006570A3 (en) Improvements in or relating to protein production
Huang et al. A mediator-free sonogenetic switch for therapeutic protein expression in mammalian cells
Nicola Candia et al. Targeting FOXP3 tumor-intrinsic effects using adenoviral vectors in experimental breast cancer
EP3492583A1 (de) Zelllaminat, verfahren zur herstellung von zelllaminat, verfahren zur bewertung der epidermalen proliferation oder differenzierung, verfahren zur bewertung der testsubstanz und biologisches implantationsmaterial
DE60333254D1 (de) Das biomolekültransduktionsmotiv sim-2-btm und dessen verwendung
WO2007089950A3 (en) Preparations of growth hormone
WO2004098508A3 (en) Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
DE50010015D1 (de) Tetrahydropyrimidin-dioxygenase-gen, dadurch kodierte polypeptide und verfahren zur deren herstellung
US20240060083A1 (en) Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method
WO2009129523A3 (en) Compositions and methods for nucleic acid delivery